The NINDS Parkinson's disease biomarkers program
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background: Neuroprotection for Parkinson's disease (PD) remains elusive. Biomarkers hold the promise of removing roadblocks to therapy development. The National Institute of Neurological Disorders and Stroke has therefore established the Parkinson's Disease Biomarkers Program to promote discovery of PD biomarkers for use in phase II and III clinical trials. Methods: Using a novel consortium design, the Parkinson's Disease Biomarker Program is focused on the development of clinical and laboratory‐based biomarkers for PD diagnosis, progression, and prognosis. Standardized operating procedures and pooled reference samples were created to allow cross‐project comparisons and assessment of batch effects. A web‐based Data Management Resource facilitates rapid sharing of data and biosamples across the research community for additional biomarker projects. Results: Eleven consortium projects are ongoing, seven of which recruit participants and obtain biosamples. As of October 2014, 1,082 participants have enrolled (620 PD, 101 with other causes of parkinsonism, 23 essential tremor, and 338 controls), 1,040 of whom have at least one biosample. Six thousand eight hundred ninety‐eight total biosamples are available from baseline, 6‐, 12‐, and 18‐month visits: 1,006 DNA, 1,661 RNA, 1,419 whole blood, 1,382 plasma, 1,200 serum, and 230 cerebrospinal fluid (CSF). Quality control analysis of plasma, serum, and CSF samples indicates that almost all samples are high quality (24 of 2,812 samples exceed acceptable hemoglobin levels). Conclusions: By making samples and data widely available, using stringent operating procedures based on existing standards, hypothesis testing for biomarker discovery, and providing a resource that complements existing programs, the Parkinson's Disease Biomarker Program will accelerate the pace of PD biomarker research. © 2015 International Parkinson and Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Parkinson's Disease Genomics Consortium (IPDGC), Nalls, M. A., Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), 23andMe, GenePD, NeuroGenetics Research Consortium (NGRC), Hussman Institute of Human Genomics (HIHG), Investigator, T. A. J. D., (CHARGE), C. F. H. A. A. R. I. G. E., North American Brain Expression Consortium (NABEC), et al. (2014) · Nature Genetics · doi:10.1038/ng.3043 · Cited by 1,895 · cited 2×
“The PDBP includes (1) biomarker hypothesis testing and collection of clinical data and biospecimens, (2) identification of novel PD biomarkers, (3) biospecimen banking and distribution, and (4) data management through the DMR.”
BackgroundSelf-citationFrontotemporal dementia and its subtypes: a genome-wide association study
Ferrari, R., Hernandez, D. G., Nalls, M. A., Rohrer, J. D., Ramasamy, A., Kwok, J. B. J., Dobson-Stone, C., Brooks, W. S., Schofield, P. R., Halliday, G. M., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70065-1 · Cited by 383
Cited by
Proteomic analysis of urinary extracellular vesicles reveal biomarkers for neurologic disease
Wang, S., Kojima, K., Mobley, J. A., & West, A. B. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.06.021 · Cited by 145
“Added value of this study Herein we characterize urinary EVs proteomes obtained from specimens biobanked under the auspices of the Parkinson's Disease Biomarker Program in clinically well-characterized subjects that lack kidney disease.”
MethodSelf-citationLiu, G., Peng, J., Liao, Z., Locascio, J. J., Corvol, J.-C., Zhu, F., Dong, X., Maple-Grødem, J., Campbell, M. C., Elbaz, A., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00847-6 · Cited by 127
“Montreal Cognitive Assessment (MoCA) 70 scores were collected in PDBP 30 , PPMI 61 study and converted to MMSE scores according to a published formula 71 .”
InfluentialSelf-citationBiomarkers in Neurodegenerative Diseases
Jeromin, A., & Bowser, R. (2017) · Advances in Neurobiology · doi:10.1007/978-3-319-57193-5_20 · Cited by 92
Study of blood linear RNA nominates CD55 and DLD as early-stage biomarkers for Parkinson's disease
Beric, A., Sahin, S., Sanchez, S., Yang, Z., Kumar, R., Alfradique-Dunham, I., Sanford, J., Western, D., Phillips, B., Budde, J. P., et al. (2026) · Brain · doi:10.1093/brain/awag014 · Cited by 2
“11,20,24,25 The publicly available datasets, PDBP, PPMI and BioFIND, were accessed through the Accelerating Medicines Partnership Parkinson’s Disease (AMP-PD) Knowledge Portal.”
Metadata
- Authors
- Rosenthal, L. S., Drake, D., Alcalay, R. N., Babcock, D., Bowman, F. D., Chen‐Plotkin, A., Dawson, T. M., Dewey, R. B., German, D. C., Huang, X., Landin, B., McAuliffe, M., Petyuk, V. A., Scherzer, C. R., Hillaire‐Clarke, C. S., Sieber, B., Sutherland, M., Tarn, C., West, A., Vaillancourt, D., Zhang, J., Gwinn, K., & on behalf of the PDBP consortium
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2015-10-07
- Volume
- 31
- Issue
- 6
- Pages
- 915-923
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W1922627767
- Cited by
- 111
- References
- 2
- FWCI
- 6.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The NINDS Parkinson's disease biomarkers program. https://app.cochat.ai/papers/10.1002/mds.26438
- The paper
- Rosenthal, L. S., Drake, D., Alcalay, R. N., Babcock, D., Bowman, F. D., Chen‐Plotkin, A., Dawson, T. M., Dewey, R. B., German, D. C., Huang, X., Landin, B., McAuliffe, M., Petyuk, V. A., Scherzer, C. R., Hillaire‐Clarke, C. S., Sieber, B., Sutherland, M., Tarn, C., West, A., . . . on behalf of the PDBP consortium. (2016). The NINDS Parkinson's disease biomarkers program. Movement Disorders. https://doi.org/10.1002/mds.26438
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.